ArticleESMO open2025
Quantitative risk of underlying disease conditions for progression from monoclonal gammopathy to multiple myeloma: a nationwide cohort study.
Article in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis nationwide real-world data cohort study developed a risk-scoring model to predict the progression of monoclonal gammopathy of undetermined significance (MGUS) to symptomatic multiple myeloma (MM) using prior disease conditions. MATERIALS AND
methodsThe Health Insurance Review and Assessment Service database, which covers nearly the entire Korean population, was utilized in this study. Out of 5361 MGUS patients, 345 (6.4%) were diagnosed with MM, with 253 (73.3%) of them progressing to symptomatic MM.
resultsWe identified female sex, chronic pulmonary disease, peptic ulcer disease, diabetes, and non-malignant hematologic disorder as significant risk factors and integrated these into the risk-scoring model. MGUS patients can be stratified into low-, intermediate-, and high-risk groups for progression to symptomatic MM using this model. The high-risk group showed a hazard ratio (HR) of 2.53 [95% confidence interval (CI) 1.70-3.75] compared with the low-risk group, and the intermediate-risk group showed an HR of 1.38 (95% CI 1.02-1.86) compared with the low-risk group.
conclusionThis scoring model will help in the early detection of MGUS patients at high risk for symptomatic MM and allow for a more efficient allocation of health care resources to those patients who require intensive monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.